28.61 USD
+0.37 (+1.31%)
At close: Feb 4, 2026
28.61 USD
0 (0%)
After Hours: 2/4/2026, 8:03:29 PM
Taking everything into account, AMPH scores 6 out of 10 in our fundamental rating. AMPH was compared to 191 industry peers in the Pharmaceuticals industry. AMPH has an excellent profitability rating, but there are some minor concerns on its financial health. AMPH may be a bit undervalued, certainly considering the very reasonable score on growth This makes AMPH very considerable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year AMPH was profitable.
- AMPH had a positive operating cash flow in the past year.
- Each year in the past 5 years AMPH has been profitable.
- Each year in the past 5 years AMPH had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 6.70%, AMPH belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
- With an excellent Return On Equity value of 14.37%, AMPH belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
- AMPH's Return On Invested Capital of 8.51% is amongst the best of the industry. AMPH outperforms 86.91% of its industry peers.
- AMPH had an Average Return On Invested Capital over the past 3 years of 12.92%. This is in line with the industry average of 12.83%.
- The 3 year average ROIC (12.92%) for AMPH is well above the current ROIC(8.51%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
- AMPH's Profit Margin of 15.43% is amongst the best of the industry. AMPH outperforms 87.43% of its industry peers.
- In the last couple of years the Profit Margin of AMPH has grown nicely.
- Looking at the Operating Margin, with a value of 20.73%, AMPH belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
- In the last couple of years the Operating Margin of AMPH has grown nicely.
- With a decent Gross Margin value of 49.36%, AMPH is doing good in the industry, outperforming 64.40% of the companies in the same industry.
- In the last couple of years the Gross Margin of AMPH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMPH is still creating some value.
- AMPH has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, AMPH has more shares outstanding
- Compared to 1 year ago, AMPH has an improved debt to assets ratio.
2.2 Solvency
- AMPH has an Altman-Z score of 2.46. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
- With a decent Altman-Z score value of 2.46, AMPH is doing good in the industry, outperforming 64.40% of the companies in the same industry.
- AMPH has a debt to FCF ratio of 5.49. This is a neutral value as AMPH would need 5.49 years to pay back of all of its debts.
- AMPH has a better Debt to FCF ratio (5.49) than 83.25% of its industry peers.
- AMPH has a Debt/Equity ratio of 0.78. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
- AMPH has a worse Debt to Equity ratio (0.78) than 70.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.46 |
ROIC/WACC0.94
WACC9.08%
2.3 Liquidity
- A Current Ratio of 3.12 indicates that AMPH has no problem at all paying its short term obligations.
- With a Current ratio value of 3.12, AMPH perfoms like the industry average, outperforming 52.88% of the companies in the same industry.
- AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of AMPH (2.21) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
- AMPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.95%.
- The Earnings Per Share has been growing by 61.62% on average over the past years. This is a very strong growth
- AMPH shows a decrease in Revenue. In the last year, the revenue decreased by -0.03%.
- The Revenue has been growing by 17.82% on average over the past years. This is quite good.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
- AMPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.14% yearly.
- The Revenue is expected to grow by 4.14% on average over the next years.
EPS Next Y-8.73%
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
EPS Next 5Y0.14%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 8.32 indicates a reasonable valuation of AMPH.
- 92.15% of the companies in the same industry are more expensive than AMPH, based on the Price/Earnings ratio.
- Compared to an average S&P500 Price/Earnings ratio of 28.25, AMPH is valued rather cheaply.
- Based on the Price/Forward Earnings ratio of 7.70, the valuation of AMPH can be described as very cheap.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 92.15% of the companies listed in the same industry.
- AMPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.50, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.32 | ||
| Fwd PE | 7.7 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaply inside the industry as 91.62% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 89.53% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.84 | ||
| EV/EBITDA | 7.75 |
4.3 Compensation for Growth
- AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.13
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
5. Dividend
5.1 Amount
- AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
28.61
+0.37 (+1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners74.02%
Inst Owner Change-1.44%
Ins Owners9.38%
Ins Owner Change-0.09%
Market Cap1.31B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts78.33
Price Target32.2 (12.55%)
Short Float %10.93%
Short Ratio10.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-0.45%
PT rev (3m)-4.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.29%
EPS NY rev (1m)0%
EPS NY rev (3m)3.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.74%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.32 | ||
| Fwd PE | 7.7 | ||
| P/S | 1.82 | ||
| P/FCF | 11.84 | ||
| P/OCF | 8.63 | ||
| P/B | 1.69 | ||
| P/tB | 6.43 | ||
| EV/EBITDA | 7.75 |
EPS(TTM)3.44
EY12.02%
EPS(NY)3.71
Fwd EY12.98%
FCF(TTM)2.42
FCFY8.44%
OCF(TTM)3.31
OCFY11.58%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.13
Graham Number36.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.46 |
F-Score5
WACC9.08%
ROIC/WACC0.94
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.73%
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.1%
EBIT Next 3Y1.2%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
What is the valuation status of AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
What is the valuation of AMPHASTAR PHARMACEUTICALS IN based on its PE and PB ratios?
The Price/Earnings (PE) ratio for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 8.32 and the Price/Book (PB) ratio is 1.69.